274 related articles for article (PubMed ID: 38281067)
1. Awakening the sleeping giant: Epstein-Barr virus reactivation by biological agents.
Indari O; Ghosh S; Bal AS; James A; Garg M; Mishra A; Karmodiya K; Jha HC
Pathog Dis; 2024 Feb; 82():. PubMed ID: 38281067
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta 1 (TGF-β1) modulates Epstein-Barr virus reactivation in absence of Helicobacter pylori infection in patients with gastric cancer.
Shukla SK; Khatoon J; Prasad KN; Rai RP; Singh AK; Kumar S; Ghoshal UC; Krishnani N
Cytokine; 2016 Jan; 77():176-9. PubMed ID: 26239415
[TBL] [Abstract][Full Text] [Related]
3. Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.
Lin Z; Swan K; Zhang X; Cao S; Brett Z; Drury S; Strong MJ; Fewell C; Puetter A; Wang X; Ferris M; Sullivan DE; Li L; Flemington EK
J Virol; 2016 Jan; 90(7):3469-79. PubMed ID: 26764001
[TBL] [Abstract][Full Text] [Related]
4. Reactivation of Epstein-Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites on the Viral Genome.
Dunn LEM; Lu F; Su C; Lieberman PM; Baines JD
J Virol; 2023 Feb; 97(2):e0189422. PubMed ID: 36744959
[TBL] [Abstract][Full Text] [Related]
5. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
[TBL] [Abstract][Full Text] [Related]
6. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
[TBL] [Abstract][Full Text] [Related]
7. Hippo signaling effectors YAP and TAZ induce Epstein-Barr Virus (EBV) lytic reactivation through TEADs in epithelial cells.
Van Sciver N; Ohashi M; Pauly NP; Bristol JA; Nelson SE; Johannsen EC; Kenney SC
PLoS Pathog; 2021 Aug; 17(8):e1009783. PubMed ID: 34339458
[TBL] [Abstract][Full Text] [Related]
8. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
[TBL] [Abstract][Full Text] [Related]
9. Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.
Chene A; Donati D; Orem J; Mbidde ER; Kironde F; Wahlgren M; Bejarano MT
Semin Cancer Biol; 2009 Dec; 19(6):411-20. PubMed ID: 19897039
[TBL] [Abstract][Full Text] [Related]
10. Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.
Gorres KL; Daigle D; Mohanram S; Miller G
J Virol; 2014 Jul; 88(14):8028-44. PubMed ID: 24807711
[TBL] [Abstract][Full Text] [Related]
11. Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.
Nawandar DM; Ohashi M; Djavadian R; Barlow E; Makielski K; Ali A; Lee D; Lambert PF; Johannsen E; Kenney SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179525
[TBL] [Abstract][Full Text] [Related]
12. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
13. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation.
Liu X; Sadaoka T; Krogmann T; Cohen JI
J Virol; 2020 May; 94(11):. PubMed ID: 32213613
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR
J Clin Pathol; 2019 Oct; 72(10):651-658. PubMed ID: 31315893
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients.
Bernal KDE; Whitehurst CB
Virus Res; 2023 Sep; 334():199157. PubMed ID: 37364815
[TBL] [Abstract][Full Text] [Related]
17. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
19. Helicobacter pylori-associated oxidant monochloramine induces reactivation of Epstein-Barr virus (EBV) in gastric epithelial cells latently infected with EBV.
Minoura-Etoh J; Gotoh K; Sato R; Ogata M; Kaku N; Fujioka T; Nishizono A
J Med Microbiol; 2006 Jul; 55(Pt 7):905-911. PubMed ID: 16772418
[TBL] [Abstract][Full Text] [Related]
20. Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation.
Tan H; Gong Y; Liu Y; Long J; Luo Q; Faleti OD; Lyu X
Biomed Pharmacother; 2023 Aug; 164():114916. PubMed ID: 37229802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
